Showing 521 - 540 results of 29,654 for search '(( 50 ((n decrease) OR (a decrease)) ) OR ( 5 ((nm decrease) OR (nn decrease)) ))', query time: 0.88s Refine Results
  1. 521
  2. 522

    Expanding Three-Coordinate Gold(I) Anticancer Agent Chemical Space by Charles E. Greif (21728091)

    Published 2025
    “…The complexes demonstrated submicromolar cytotoxic activity against human breast cancer cells MDA-MB-231 or MDA-MB-468 with IC<sub>50</sub>’s in the range of 0.4–5.0 μM. Complex <b>2e</b> shows high potency in vitro and decreases 3D-breast cancer mammosphere viability. …”
  3. 523
  4. 524
  5. 525
  6. 526
  7. 527
  8. 528
  9. 529
  10. 530
  11. 531
  12. 532
  13. 533
  14. 534

    CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

    Published 2020
    “…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
  15. 535

    Decrease in Vitamin D Status in the Greenlandic Adult Population from 1987–2010 by Nina O. Nielsen (490187)

    Published 2014
    “…A sub-sample (n = 330) donated a blood sample in 1987 which allowed assessment of time trends in vitamin D status.…”
  16. 536
  17. 537

    Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain. by Caio Maximino (100467)

    Published 2014
    “…A negative correlation is found between the decrease in serotonin turnover and the increase in time on white produced by a drug (r<sup>2</sup> = 0.5688, p = 0.0073).…”
  18. 538

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  19. 539
  20. 540